ANI Pharmaceuticals, Inc. (ANIP) News

ANI Pharmaceuticals, Inc. (ANIP): $36.86

-0.96 (-2.54%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ANIP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 509

in industry

Filter ANIP News Items

ANIP News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ANIP News Highlights

  • For ANIP, its 30 day story count is now at 3.
  • Over the past 11 days, the trend for ANIP's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • LINK are the most mentioned tickers in articles about ANIP.

Latest ANIP News From Around the Web

Below are the latest news stories about Ani Pharmaceuticals Inc that investors may wish to consider to help them evaluate ANIP as an investment opportunity.

7 Overbought Stocks to Be Very Careful of Right Now

While the market rally this year has been incredible, worrying developments suggest investors should watch out for overbought stocks.

Josh Enomoto on InvestorPlace | October 1, 2021

ANI Pharmaceuticals to Present at Cantor Virtual Global Healthcare Conference 2021

ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at the Cantor Virtual Global Healthcare Conference 2021 as follows: Date: Thursday, September 30, 2021 Time: 8:00 a.m. ET Webcast Link: https://wsw.com/webcast/cantor12/anip/2073680

Wallstreet:Online | September 20, 2021

ANI Pharma Launches Nebivolol Tablets, 2.5 Mg, 5 Mg, 10 Mg, And 20 Mg

WASHINGTON (dpa-AFX) - ANI Pharmaceuticals, Inc. (ANIP) announced Friday the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg. It is simultaneously launched from two manufacturing sites

FinanzNachrichten | September 17, 2021

ANI Pharmaceuticals Announces Launch of Nebivolol Tablets

BAUDETTE, Minn., September 17, 2021--ANI Pharmaceuticals, Inc. ("ANI" or the "Company") (Nasdaq: ANIP) today announced the launch of Nebivolol Tablets, 2.5 mg, 5 mg, 10 mg, and 20 mg.

Yahoo | September 17, 2021

Vaginal Fungi Infections Treatment Market Likely To Boost Future Growth By 2026 | Pfizer Inc.,Bausch Health Companies Inc.,ANI Pharmaceuticals,Hikma Pharmaceuticals Plc

Vaginal Fungi Infections Treatment Market Growing Popularity and Emerging Trends The report on the global Vaginal Fungi Infections Treatment Market is derived from intense research, conducted by a team of industry professionals. The report covers briefly the products or services

OpenPR | September 14, 2021

Is ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Shareholder Ownership Skewed Towards Insiders?

If you want to know who really controls ANI Pharmaceuticals, Inc. ( NASDAQ:ANIP ), then you'll have to look at the...

Yahoo | September 3, 2021

ANI Pharmaceuticals Announces FDA Acceptance of Purified Cortrophin® Gel Supplemental New Drug Application for Multiple Indications Including Multiple Sclerosis, Rheumatoid Arthritis, and Nephrotic Syndrome

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq:ANIP) today announced that the Companys supplemental New Drug Application (sNDA) for Purified Cortrophin® Gel (Cortrophin Gel) has been accepted by the U.S. Food and Drug Administration (FDA) for review. FDAs acceptance of our sNDA for Cortrophin Gel marks a significant milestone for ANI. With a PDUFA target action date of October 29, 2021, we are one step closer to bringing a much-needed produ

Business Wire | August 31, 2021

ANI Pharmaceuticals Says Its Supplemental NDA For Purified Cortrophin Gel Accepted

(RTTNews) - ANI Pharmaceuticals, Inc. (ANIP) on Tuesday said the FDA has accepted the company''s supplemental New Drug Application for Purified Cortrophin Gel for multiple indications including multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. A decision by the FDA on the application is expected on October 29, 2021.

Business Insider Markets | August 31, 2021

ANI Pharmaceuticals Reports Second Quarter 2021 Results

BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ: ANIP) today announced business highlights and financial results for the three and six months ended June 30, 2021. Second Quarter and Recent Business Highlights: The Company refiled its supplemental new drug application (sNDA) for Cortrophin® Gel with the U.S. Food and Drug Administration (FDA or the Agency) on June 29, 2021; goal date is October 29, 2021; Acquisition of Novitium Pharma LLC (Novi

Business Wire | August 6, 2021

ANI Pharmaceuticals, inc (ANIP) Q2 2021 Earnings Call Transcript

ANIP earnings call for the period ending June 30, 2021.

The Motley Fool | August 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7729 seconds.